Celcuity Inc. (CELC)
Nasdaq · Common stock · Services-Medical Laboratories
As of Oct 22, 12:26 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow CELC in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on CELC and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
CELC at a glance
Key statistics
$3.01B
Market capitalization
- Previous close
- $61.56
- Open
- $64.56
- Day range
- $61.92 – $66.65
- Volume
- 673.4K
- Average volume (30 sessions)
- 1.55M
- Shares outstanding
- 48.93M
- Earnings per share
- $(4.63)
- Beta (1 year, vs SPY)
- 1.28
Where the price sits in its year
52-week range
13% of the range
- Below the 52-week high
- -56.0%
- Above the 52-week low
- +24.1%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $68.68-10.4%
- 50-day average
- $81.03-24.0%
- 200-day average
- $102.02-39.7%
Between the conventional 30 and 70 bands.
+2.8%
1 week
-26.8%
1 month
-30.3%
3 months
-38.3%
Year to date
-12.8%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with CELC
CELC on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on CELC.
See the plans →
Every planScreen names like CELC
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on CELC
Put CELC on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on CELC
See whether there is an open premium alert on CELC, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
CELC headlines
- Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
GlobeNewswire Inc. · Jul 14, 2026
- Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
GlobeNewswire Inc. · Jun 3, 2026
- Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
GlobeNewswire Inc. · Mar 9, 2026
- Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
GlobeNewswire Inc. · Oct 18, 2025
- Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
GlobeNewswire Inc. · Oct 18, 2025
- Celcuity To Participate in Jefferies Global Healthcare Conference
GlobeNewswire Inc. · Jun 3, 2024
- Celcuity Announces Pricing of Underwritten Common Stock Offering
GlobeNewswire Inc. · May 30, 2024
- Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
GlobeNewswire Inc. · May 30, 2024
SEC Form 4, most recent first
Insider filings
Furcht Leo
−250
Director · Option exercise
· Oct 7, 2026
Furcht Leo
+250
Director · Option exercise
$1.90K · Oct 7, 2026
GRYSKA DAVID W
+893
Director · Grant or award
· Oct 1, 2026
Laing Lance G.
+20.0K
Chief Science Officer, Director · Grant or award
· Aug 14, 2026
Hahne Vicky
+16.0K
Chief Financial Officer · Grant or award
· Aug 14, 2026
Hahne Vicky
+10.0K
Chief Financial Officer · Grant or award
· Aug 14, 2026
Laing Lance G.
+10.0K
Chief Science Officer, Director · Grant or award
· Aug 14, 2026
Sullivan Brian F.
+120.0K
Chief Executive Officer, Director · Grant or award
· Aug 14, 2026
About Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Services-Medical Laboratories
- Headquarters
- Minneapolis, MN
- Employees
- 155
- Listed since
- Sep 20, 2017
- Website
- celcuity.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.